JP2020524143A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524143A5
JP2020524143A5 JP2019569758A JP2019569758A JP2020524143A5 JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5 JP 2019569758 A JP2019569758 A JP 2019569758A JP 2019569758 A JP2019569758 A JP 2019569758A JP 2020524143 A5 JP2020524143 A5 JP 2020524143A5
Authority
JP
Japan
Prior art keywords
composition according
bioactive agent
lipid
oil
sorbitan ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524143A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037783 external-priority patent/WO2018232257A1/en
Publication of JP2020524143A publication Critical patent/JP2020524143A/ja
Publication of JP2020524143A5 publication Critical patent/JP2020524143A5/ja
Priority to JP2024000126A priority Critical patent/JP2024029173A/ja
Pending legal-status Critical Current

Links

JP2019569758A 2017-06-15 2018-06-15 ナノ構造脂質担体、安定エマルジョン、およびその使用 Pending JP2020524143A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000126A JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201762520204P 2017-06-15 2017-06-15
US62/520,204 2017-06-15
US201762540973P 2017-08-03 2017-08-03
US62/540,973 2017-08-03
US201762556291P 2017-09-08 2017-09-08
US62/556,291 2017-09-08
US201762563544P 2017-09-26 2017-09-26
US62/563,544 2017-09-26
US201762582859P 2017-11-07 2017-11-07
US62/582,859 2017-11-07
US201862622748P 2018-01-26 2018-01-26
US201862622755P 2018-01-26 2018-01-26
US62/622,748 2018-01-26
US62/622,755 2018-01-26
US201862669262P 2018-05-09 2018-05-09
US62/669,262 2018-05-09
US201862677336P 2018-05-29 2018-05-29
US62/677,336 2018-05-29
US201862680454P 2018-06-04 2018-06-04
US62/680,454 2018-06-04
PCT/US2018/037783 WO2018232257A1 (en) 2017-06-15 2018-06-15 Nanostructured lipid carriers and stable emulsions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000126A Division JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Publications (2)

Publication Number Publication Date
JP2020524143A JP2020524143A (ja) 2020-08-13
JP2020524143A5 true JP2020524143A5 (enExample) 2021-07-29

Family

ID=62948328

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019569758A Pending JP2020524143A (ja) 2017-06-15 2018-06-15 ナノ構造脂質担体、安定エマルジョン、およびその使用
JP2024000126A Pending JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000126A Pending JP2024029173A (ja) 2017-06-15 2024-01-04 ナノ構造脂質担体、安定エマルジョン、およびその使用

Country Status (13)

Country Link
US (3) US11141377B2 (enExample)
EP (1) EP3638207B1 (enExample)
JP (2) JP2020524143A (enExample)
KR (2) KR102673794B1 (enExample)
CN (1) CN111315362A (enExample)
AU (1) AU2018285694B2 (enExample)
BR (1) BR112019026615B1 (enExample)
CA (1) CA3067224A1 (enExample)
ES (1) ES3003260T3 (enExample)
IL (1) IL271384B2 (enExample)
MX (4) MX2019015076A (enExample)
WO (1) WO2018232257A1 (enExample)
ZA (1) ZA201908207B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018285694B2 (en) * 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof
WO2020150274A1 (en) 2019-01-15 2020-07-23 Nant Holdings Ip, Llc Aragonite compositions, methods, and uses thereof
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4058581A1 (en) 2019-11-15 2022-09-21 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CN115955959A (zh) * 2020-02-26 2023-04-11 康普萨姆公司 纳米结构脂质载体递送系统、组合物和方法
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
CN111494619B (zh) * 2020-04-26 2022-03-18 南京农业大学 一种基于角鲨烯的阳离子纳米结构脂质载体免疫佐剂的制备方法
WO2022051022A1 (en) 2020-09-04 2022-03-10 Infectious Disease Research Institute Co-lyophilized rna and nanostructured lipid carrier
CA3173951A1 (en) 2020-09-04 2022-03-10 Emily VOIGT Genetically-adjuvanted rna vaccines
JP2024501949A (ja) * 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法
WO2022251406A1 (en) * 2021-05-28 2022-12-01 The Regents Of The University Of Michigan Combined agonist adjuvant for coronavirus vaccine
IN202121031414A (enExample) * 2021-07-13 2023-01-13
CA3226276A1 (en) 2021-07-29 2023-02-02 Nantcell, Inc. Modified t cell receptors for the prevention and treatment of viral infections and cancer
KR102681030B1 (ko) * 2021-08-02 2024-07-02 한국화학연구원 올리고뉴클레오타이드가 봉입된 나노입자, 이의 제조방법 및 이를 포함하는 약학적 제제
WO2023023332A1 (en) * 2021-08-20 2023-02-23 Thomas Jefferson University Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same
AU2022349634A1 (en) * 2021-09-22 2024-04-11 Hdt Bio Corp. Nucleic acid sensor agonist compositions and uses thereof
EP4404957A4 (en) * 2021-09-22 2025-08-06 Hdt Bio Corp CANCER THERAPY COMPOSITIONS AND THEIR USES
AU2022351009A1 (en) * 2021-09-22 2024-04-11 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3232648A1 (en) * 2021-09-22 2023-04-06 Amit Praful Khandhar Compositions and methods for enhanced protein production
AU2022352486A1 (en) * 2021-09-22 2024-04-11 Hdt Bio Corp. Dried nanoparticle compositions
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
WO2023228116A1 (en) 2022-05-24 2023-11-30 Access To Advanced Health Institute Intranasal administration of thermostable rna vaccines
WO2024053934A1 (ko) * 2022-09-05 2024-03-14 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用
CN116392586B (zh) * 2023-04-12 2025-06-24 江苏中慧元通生物科技股份有限公司 一种纳米乳佐剂
WO2024216214A1 (en) * 2023-04-14 2024-10-17 BioNTech SE Rna for preventing or treating tuberculosis
WO2025006870A1 (en) * 2023-06-29 2025-01-02 Rigimmune Inc. Novel formulations
WO2025244961A1 (en) * 2024-05-22 2025-11-27 Merck Sharp & Dohme Llc Processes for making stable nanoemulsion adjuvants

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
DK0414374T3 (da) 1989-07-25 1998-03-09 Smithkline Beecham Biolog Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
DE122007000023I1 (de) 1991-07-19 2007-08-09 Univ Queensland St Lucia Impfsstoff gegen Humanes Papillomavirus (typ 18)
ES2129461T3 (es) 1991-11-16 1999-06-16 Smithkline Beecham Biolog Proteina hibrida entre cs de plasmodium y hbsag.
EP0647140B1 (en) 1992-06-25 2007-12-12 Georgetown University Papillomavirus vaccines
US5786148A (en) 1996-11-05 1998-07-28 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a novel prostate-specific kallikrein
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ES2242955T4 (es) 1993-03-09 2010-04-12 The University Of Rochester Produccion de la proteina de la capside del virus del papiloma humano y particulas de tipo viral.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
DE59511047D1 (de) 1994-10-07 2006-06-14 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
JP3958360B2 (ja) 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5955306A (en) 1996-09-17 1999-09-21 Millenium Pharmaceuticals, Inc. Genes encoding proteins that interact with the tub protein
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
DE69831222T2 (de) 1997-02-25 2006-07-13 Corixa Corp., Seattle Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100760221B1 (ko) 1997-11-28 2007-10-30 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CN1227360C (zh) 1998-02-05 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
AU3560399A (en) 1998-04-15 1999-11-01 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
TW200728465A (en) 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
US6533949B1 (en) 2000-08-28 2003-03-18 Nanopass Ltd. Microneedle structure and production method therefor
CA2421683C (en) 2000-09-28 2009-09-15 Chiron Corporation Microparticles for delivery of the heterologous nucleic acids
DE60333035D1 (de) 2002-12-23 2010-07-29 Vical Inc Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
US7998119B2 (en) 2003-11-18 2011-08-16 Nano Pass Technologies Ltd. System and method for delivering fluid into flexible biological barrier
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
JP5378350B2 (ja) 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌(Mycobacteriumtuberculosis)ポリペプチドおよびその融合物を含む免疫原性組成物
WO2009088401A2 (en) * 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
MX348474B (es) 2009-12-23 2017-06-14 Novartis Ag * Lipidos, composiciones de lipido, y metodos de uso de los mismos.
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
RU2625546C2 (ru) * 2010-07-06 2017-07-14 Новартис Аг Катионные эмульсии "масло-в-воде"
ES2586580T3 (es) 2010-07-06 2016-10-17 Glaxosmithkline Biologicals Sa Inmunización de mamíferos grandes con dosis bajas de ARN
AU2012280901B2 (en) * 2011-07-06 2016-11-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
CN103764121A (zh) * 2011-07-06 2014-04-30 诺华股份有限公司 用于递送rna分子的具有有用n:p比的脂质体
RU2649133C2 (ru) * 2011-07-06 2018-03-29 Новартис Аг Катионные эмульсии масло-в-воде
US10322089B2 (en) * 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
US8809388B2 (en) * 2012-11-06 2014-08-19 Brandeis University Vegetable oil composition containing palm mid-fraction fat and method of reducing plasma cholesterol
HK1214962A1 (zh) * 2013-01-10 2016-08-12 Seqirus UK Limited 流感病毒免疫原性组合物及其应用
AU2017268394A1 (en) * 2016-05-18 2019-01-03 Modernatx, Inc. Polynucleotides encoding relaxin
AU2018285694B2 (en) * 2017-06-15 2025-04-10 Access To Advanced Health Institute Nanostructured lipid carriers and stable emulsions and uses thereof

Similar Documents

Publication Publication Date Title
JP2020524143A5 (enExample)
Chatzikleanthous et al. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines
JP7333563B2 (ja) 脂質ナノ粒子
JP6077509B2 (ja) 改良されたアミノ脂質および核酸の送達方法
Kim et al. Nanotechnology and vaccine development
Davidsen et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses
JP2013531680A5 (enExample)
DK2729127T3 (en) METHODS FOR LIPOSOMES PREPARATION
RU2014104092A (ru) Эмульсии типа "масло в воде", которые содержат нуклеиновые кислоты
US20170049702A1 (en) Method to Enhance an Immune Response of Nucleic Acid Vaccination
JP2023518976A (ja) Rnaを送達するための組成物および方法
CN101909581A (zh) 固醇修饰的两亲脂质
EP3147277B1 (en) Lipid membrane structure for sirna intracellular delivery
Nordly et al. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo
CN1980638B (zh) 用糖脂稳定基于脂质的佐剂制剂的组合物和方法
Perrie et al. Surfactant vesicle-mediated delivery of DNA vaccines via the subcutaneous route
Wang et al. Advances in the study of LNPs for mRNA delivery and clinical applications
Ahmad et al. Liposomes and niosomes for targeted drug and gene delivery systems
WO2024209013A1 (en) Lipid nanoparticle compositions
Nie et al. Synthetic nanomaterials for spleen-specific mRNA delivery
Wölk et al. Investigation of binary lipid mixtures of a three-chain cationic lipid with phospholipids suitable for gene delivery
JP5390059B2 (ja) 無菌ポリヌクレオチド系薬剤の製造方法
Porte et al. A molecular view of lipid nanoparticles: insights into their morphology and structural plasticity
JPWO2018181542A1 (ja) アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット
RU2019142632A (ru) Наноструктурированные липидные носители и стабильные эмульсии и их применения